Ciprofloxacin safety in a pediatric population

Area of Science:

• Pediatric pharmacology
• Drug safety surveillance
• Antibiotic-associated adverse events

Background:

• Ciprofloxacin is a widely used fluoroquinolone antibiotic.
• Concerns exist regarding potential toxicities, particularly musculoskeletal, in pediatric populations.
• Limited data are available on the comprehensive safety profile of ciprofloxacin in children.

Purpose of the Study:

• To estimate the risk of musculoskeletal toxicities linked to ciprofloxacin in pediatric patients.
• To assess the incidence of hepatic and renal disorders associated with ciprofloxacin therapy in children.
• To evaluate the overall safety of ciprofloxacin in a young population.

Main Methods:

• Retrospective study design utilizing two resource databases.
• Identification of over 1700 pediatric patients (<=17 years) prescribed ciprofloxacin between 1988 and 1993.
• Adverse events were defined as those requiring physician referral or hospitalization within 45 days of prescription.

Main Results:

• No cases of newly diagnosed acute arthritis were identified as likely ciprofloxacin-induced.
• No serious liver or kidney diseases were attributed to ciprofloxacin therapy in this cohort.
• One case of hemolytic-uremic syndrome was noted, potentially exacerbated by ciprofloxacin.

Conclusions:

• Surveillance of ciprofloxacin use in pediatric patients did not reveal serious or elevated rates of adverse events.
• The study failed to demonstrate a significant risk of joint toxicity associated with ciprofloxacin in children.
• Overall, ciprofloxacin appears to have a generally favorable safety profile in the pediatric population studied.